Clarity receives $3.26 million R&D tax incentive refund
Sydney, Australia 4 February 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that it has received a $3,262,861 Research and Development (R&D) tax refund as part of the Australian Federal Government’s R&D tax incentive, recognising the R&D undertaken by Clarity…